Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03040570
Other study ID # 15IA35
Secondary ID
Status Completed
Phase N/A
First received November 21, 2016
Last updated February 22, 2018
Start date March 4, 2017
Est. completion date July 1, 2017

Study information

Verified date February 2018
Source Great Ormond Street Hospital for Children NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A feasibility study to determine if it is possible to perform a safe, adequately powered, and affordable multi-centre study in critically ill children comparing current practice of liberal targets for systemic oxygen levels with more conservative targets.


Description:

Around 19,000 critically ill children are admitted to paediatric intensive care units (PICU) each year in the UK. A large number of these children need breathing support, and this is usually provided through an invasive machine called a 'ventilator'. Clinicians make decisions for treatment based on how much oxygen their patient has in their blood (this is called oxygen saturation or oxygenation) and currently the amount of oxygen critically ill children need is not fully understood. This means that some clinicians use a lower oxygen saturation target, and others, a higher target. This may be problematic as research in neonates (babies) and adults has shown that oxygen saturation levels can influence a patient's chance of survival, how long they stay in hospital and healthcare costs.

Response to oxygen is different in babies, children and adults. This means that the results from the neonatal and adult research are unlikely to be valid or applicable in children due to age-related differences. Urgent high quality clinical evidence is therefore needed to inform on the best targets of oxygenation during critical illness in children.

As large clinical trials are expensive to conduct, it is important to demonstrate that a large-scale trial can be done and that the different components of a trial can all work together. Therefore, the Oxy-PICU study is a 'pilot randomised clinical trial' (a smaller version of the trial we would like to conduct) and will test the feasibility and safety of conducting a large scale trial comparing a restrictive oxygen saturation target (88-92%) with a more liberal oxygen saturation target (>94%). Oxy-PICU will also collect blood and urine samples to allow for in depth study of the biology of the different oxygenation targets.

The pilot trial will take place at three PICUs (two in London and one in Southampton) and aims to include between 115-125 eligible children over six months. Given the emergency nature of these children and the need to provide immediate care, informed consent will be sought after the children are entered into the study (this is known as deferred consent).


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date July 1, 2017
Est. primary completion date June 25, 2017
Accepts healthy volunteers No
Gender All
Age group 39 Weeks to 15 Years
Eligibility Inclusion Criteria:

- less than 16 years and > 38 weeks corrected gestational age

- receiving supplemental oxygen for abnormal gas exchange

- emergency admission accepted to a participating paediatric intensive care unit (PICU) requiring mechanical ventilation within first 6 hours of face-to-face contact with PICU staff or transport team

Exclusion Criteria:

- recruited to Oxy-PICU in a previous admission

- brain pathology/injury as a primary reason for admission (e.g traumatic brain injury, post-cardiac arrest, stroke, convulsive status epilepticus without aspiration)

- known pulmonary hypertension

- known or suspected sickle cell disease

- known or suspected uncorrected congenital cardiac disease

- End-of-life care plan in place with limitation of resuscitation

- not expected to survive PICU admission

- receiving long-term mechanical ventilation prior to this admission (non-invasive ventilation or invasive ventilation)

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Conservative oxygenation target
Participants allocated to the conservative oxygenation target group will receive supplemental oxygen and ventilator settings at the discretion of the treating clinical team with the aim of peripheral oxygen saturations remaining 88-92% (inclusive).
Liberal oxygenation target
Participants allocated to the liberal oxygenation target group will receive supplemental oxygen and ventilator settings at the discretion of the treating clinical team with the aim of peripheral oxygen saturations remaining >94%.

Locations

Country Name City State
United Kingdom Great Ormond Street Hospital for Children London
United Kingdom St Mary's Hospital London
United Kingdom Southampton General Hospital Southampton

Sponsors (6)

Lead Sponsor Collaborator
Great Ormond Street Hospital for Children NHS Foundation Trust Intensive Care National Audit & Research Centre, St Mary's Hospital, London, University College, London, University Hospital Southampton NHS Foundation Trust, University of Southampton

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of eligible patients recruited per site per month Baseline
Secondary Proportion of parents/legal representatives refusing deferred consent Through study completion, an average of 24 hours
Secondary Proportion of eligible patients randomised Baseline
Secondary Distribution of time to randomisation Baseline
Secondary Proportion of systemic oxygen saturations within the target range in each group Through study completion, an average of 72 hours
Secondary Proportion of patients in each arm requiring other treatments influencing tissue oxygen delivery (blood transfusion, inotropic support) Through study completion, an average of 72 hours
Secondary Length of ventilation - proportion of randomised patients with outcome available in each group Through study completion, an average of 2 days
Secondary Length of ventilation - mean (standard deviation) in each group Through study completion, an average of 2 days
Secondary Length of ventilation - median and quartiles in each group. Through study completion, an average of 2 days
Secondary Observed adverse events 28 days
Secondary Time taken for data collection and entry 28 days
Secondary Measurement of ischemia-modified albumin (plasma) 72 hours
Secondary Measurement of malondialdehyde (plasma) 72 hours
Secondary Measurement of total antioxidant status (plasma) 72 hours
Secondary Length of PICU stay - proportion of randomised patients with outcome available in each group Through study completion, an average of 2 days
Secondary Length of PICU stay - mean (standard deviation) in each group. Through study completion, an average of 2 days
Secondary Length of PICU stay - median and quartiles in each group. Through study completion, an average of 2 days
Secondary Hospital mortality - proportion of randomised patients with outcome available in each group Through study completion, an average of 2 days
Secondary Hospital mortality - number (percentage) in each group. Through study completion, an average of 2 days
Secondary PICU mortality - proportion of randomised patients with outcome available in each group Through study completion, an average of 2 days
Secondary PICU mortality - number (percentage) in each group. Through study completion, an average of 2 days
Secondary Days of organ specific support - proportion of randomised patients with outcome available in each group Through study completion, an average of 2 days
Secondary Days of organ specific support - mean (standard deviation) in each group Through study completion, an average of 2 days
Secondary Days of organ specific support - median and quartiles in each group Through study completion, an average of 2 days
Secondary Measurement of hypoxia-inducible factor-1 alpha mRNA expression (leukocytes) 72 hours
See also
  Status Clinical Trial Phase
Recruiting NCT04498598 - Structural Modification In Supraglottic Airway Device N/A
Completed NCT05532670 - N600X Low Saturation Accuracy Validation
Enrolling by invitation NCT04106401 - Intravascular Volumes in Hypoxia During Antarctic Confinement N/A
Recruiting NCT05883137 - High-flow Nasal Oxygenation for Apnoeic Oxygenation During Intubation of the Critically Ill
Not yet recruiting NCT05817448 - Hypoxia-induced Autophagy in the Pathogenesis of MAP
Recruiting NCT02661152 - DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC. Phase 3
Terminated NCT02801162 - Evaluation of Accuracy and Precision of a New Arterial Blood Gas Analysis System Blood in Comparison With the Reference Standard N/A
Completed NCT02943863 - Regional Ventilation During High Flow Nasal Cannula and Conventional Nasal Cannula in Patients With Hypoxia N/A
Not yet recruiting NCT02201875 - Intrinsic Periodic Pattern of Breathing N/A
Completed NCT01922401 - Inverse Ratio Ventilation on Bariatric Operation N/A
Completed NCT02105298 - Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study) N/A
Active, not recruiting NCT01681238 - Goal-directed Therapy in High-risk Surgery N/A
Completed NCT01463527 - Using Capnography to Reduce Hypoxia During Pediatric Sedation N/A
Completed NCT01507623 - Value of Capnography During Nurse Administered Propofol Sedation (NAPS) N/A
Withdrawn NCT00638040 - The Gene Expression Studies of the Role of Tumor Microenvironments in Tumor Progression N/A
Active, not recruiting NCT06097754 - Intermittent Exogenous Ketosis (IEK) at High Altitude N/A
Completed NCT04589923 - The VISION-Acute Study
Completed NCT05044585 - Evaluation of RDS MultiSense® in Desaturation Analysis in Healthy Volunteers N/A
Completed NCT03659513 - The Effect of ECMO on the Pharmacokinetics of the Drugs and Their Clinical Efficacy
Completed NCT03221387 - Sleep and Daytime Use of Humidified Nasal High-flow Oxygen in COPD Outpatients N/A